logo
Healthy dad who smelt sugar ended up with brain cancer

Healthy dad who smelt sugar ended up with brain cancer

Costa initially suspected he might be dealing with epilepsy, something he had experienced earlier in life.
Antonio said that, as a family, they didn't really look into it but advised his dad to get a scan, thinking it was likely linked to his past epilepsy.
However, in April, the family faced a horrible truth - Costa was found to have stage 4 brain cancer.
Antonio said: "We were shellshocked. We didn't really know how to take it.
"We were worried, scared, nervous, but then still trying to get to grips with the situation and what was going on because he had no symptoms. It just kind of proves that you can be a fit and healthy man, yet still have something wrong with you."
Antonio continued: "My dad is a fighter. He's always fought all of his life. His nickname has been Rambo all of his life, because he's just known to get through any battle he's had to face.
"He was shocked. He was taken aback. He was stunned. He didn't know how to react and I still don't think he knows how to react. The only things the NHS offer, which is the massive problem and why we're doing the fundraising, is a course of radiotherapy and chemotherapy. In the last 20 years the treatments haven't changed for glioblastomas in the UK.
"So it's quite a scary thing to be diagnosed with, knowing that there's not much the NHS can do. Put it this way, they're telling us in the consultancy meetings not to cut back on anything and just enjoy your life, in the most harrowing way possible."
The family refuses to give up hope. Inspired by success stories, they are exploring alternative therapies abroad, such as DC vaccine therapy in Munich, oncothermia as part of a clinical trial in London, a three-phase immunotherapy programme at the IZOK Clinic in Cologne, and peptide vaccine treatment from a specialist lab in Tübingen.
The family needs to raise around £464,000 for these treatments, and have already managed to fundraise more than £260,000.
If you want the link to his GoFundMe, follow this link.
Costa has recently completed his radiotherapy and chemotherapy courses and has demonstrated an encouraging response, although it remains too early to assess the complete impact of these treatments.
Antonio said: "It's harrowing what's going on with treatments for GMBs and the progress they've made over the last 20 years, not just for my dad but for every other patient who is suffering with the same thing.
"It's almost like you get this and 'bye-bye', because the diagnosis is a grade four brain tumour glioblastoma, that is unmethylated and it's IDH wild type. Those two things mean it's the worst type of brain cancer you can get. But in reality there is so much that can be offered."
Recommended reading:
The overwhelming wave of solidarity from their community has profoundly touched the family.
Antonio continued: "My dad is a hard-working, typical father figure. Raised three kids, he's got his grandkids. He's loving, he's generous, he'll do anything for anybody.
"He's very giving, which is why I think he's reaped the rewards now in terms of people giving back and the GoFundMe. He loves rugby, he used to coach the local football and rugby team when I was growing up.
"He's so down to earth, always looking to help people - good morals, good values - but he's a hard worker and he'll fight this just like any battle he has faced before. And he's faced some battles. So this is just going to be another one, it's the toughest test yet."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

OpenAI stops ChatGPT from telling people to break up with partners
OpenAI stops ChatGPT from telling people to break up with partners

The Guardian

timean hour ago

  • The Guardian

OpenAI stops ChatGPT from telling people to break up with partners

ChatGPT will not tell people to break up with their partner and will encourage users to take breaks from long chatbot sessions, under new changes to the artificial intelligence tool. OpenAI, ChatGPT's developer, said the chatbot would stop giving definitive answers to personal challenges and would instead help people to mull over problems such as potential breakups. 'When you ask something like: 'Should I break up with my boyfriend?' ChatGPT shouldn't give you an answer. It should help you think it through – asking questions, weighing pros and cons,' said OpenAI. The US company said new ChatGPT behaviour for dealing with 'high-stakes personal decisions' would be rolled out soon. OpenAI admitted this year that an update to ChatGPT had made the groundbreaking chatbot too agreeable and altered its tone. In one reported interaction before the change, ChatGPT congratulated a user for 'standing up for yourself' when they claimed they had stopped taking their medication and left their family – who the user had thought were responsible for radio signals emanating from the walls. In the blog post, OpenAI admitted that there had been instances where its advanced 4o model had not recognised signs of delusion or emotional dependency – amid concerns that chatbots are worsening people's mental health crises. The company said it was developing tools to detect signs of mental or emotional distress so ChatGPT can direct people to 'evidence-based' resources for help. A recent study by NHS doctors in the UK warned that AI programs could amplify delusional or grandiose content in users vulnerable to psychosis. The study, which has not been peer reviewed, said the programs' behaviour could be because the models were designed to 'maximise engagement and affirmation'. The study added that even if some individuals benefited from AI interactions, there was a concern the tools could 'blur reality boundaries and disrupt self-regulation'. OpenAI added that from this week it would send 'gentle reminders' to take a screen break to users engaging in long chatbot sessions, similar to screen-time features deployed by social media companies. OpenAI also said it had convened an advisory group of experts in mental health, youth development and human-computer-interaction to guide its approach. The company has worked with more than 90 doctors, including psychiatrists and paediatricians, to build frameworks for evaluating 'complex, multi-turn' chatbot conversations. 'We hold ourselves to one test: if someone we love turned to ChatGPT for support, would we feel reassured? Getting to an unequivocal 'yes' is our work,' said the blog post. The ChatGPT alterations were announced amid speculation that a more powerful version of the chatbot is imminent. On Sunday Sam Altman, OpenAI's chief executive, shared a screenshot of what appeared to be the company's latest AI model, GPT-5.

Treatment for advanced womb cancer ‘major step forward'
Treatment for advanced womb cancer ‘major step forward'

South Wales Argus

timean hour ago

  • South Wales Argus

Treatment for advanced womb cancer ‘major step forward'

Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'

Treatment for advanced womb cancer ‘major step forward'
Treatment for advanced womb cancer ‘major step forward'

South Wales Guardian

timean hour ago

  • South Wales Guardian

Treatment for advanced womb cancer ‘major step forward'

Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store